Effect of hepatic impairment on the pharmacokinetics and pharmacodynamics of a single dose of rivaroxaban, an oral, direct Factor Xa inhibitor-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Effect of hepatic impairment on the pharmacokinetics and pharmacodynamics of a single dose of rivaroxaban, an oral, direct Factor Xa inhibitor

Published:2013-06-20 Issue:1 Volume:76 Page:89-98
ISSN:0306-5251
Container-title:British Journal of Clinical Pharmacology
language:en
Short-container-title:Br J Clin Pharmacol

Author:

Kubitza Dagmar¹,Roth Angelika¹,Becka Michael²,Alatrach Abir³,Halabi Atef³,Hinrichsen Holger⁴,Mueck Wolfgang¹

Affiliation:

1. Clinical Pharmacology; Bayer Pharma AG; 42096; Wuppertal

2. Department of Biometry, Pharmacometry; Bayer Pharma AG; Wuppertal

3. Clinical Research Services (CRS) Kiel GmbH; 24105; Kiel

4. Gastroenterologisch-Hepatologisches Zentrum Kiel; 24105; Kiel; Germany

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/bcp.12054/fullpdf

Reference36 articles.

1. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: executive summary. A report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients with Atrial Fibrillation);Fuster;Eur Heart J,2006

2. Prevention of venous thromboembolism: American College of Chest Physicians evidence-based clinical practice guidelines (8th Edition);Geerts;Chest,2008

3. Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians evidence-based clinical practice guidelines (8th Edition);Singer;Chest,2008

4. The primary and secondary prevention of coronary artery disease: American College of Chest Physicians evidence-based clinical practice guidelines (8th Edition);Becker;Chest,2008

5. Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians evidence-based clinical practice guidelines (8th Edition);Kearon;Chest,2008

Cited by 169 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Anticoagulation for stroke prevention in atrial fibrillation and treatment of venous thromboembolism and portal vein thrombosis in cirrhosis: guidance from the SSC of the ISTH;Journal of Thrombosis and Haemostasis;2024-09

2. Beyond Anticoagulation: A Comprehensive Review of Non-Vitamin K Oral Anticoagulants (NOACs) in Inflammation and Protease-Activated Receptor Signaling;International Journal of Molecular Sciences;2024-08-10

3. Direct oral anticoagulants in cirrhosis: Rationale and current evidence;JHEP Reports;2024-08

4. Chinese Guidelines for the Diagnosis and Management of Atrial Fibrillation;Cardiology Discovery;2024-05-29

5. Effectiveness of edoxaban in portal vein thrombosis associated with liver cirrhosis;Scientific Reports;2024-05-11

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3